{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-049485","form_type":"8-K","ticker":"PAHC","cik":"0001069899","company_name":"PHIBRO ANIMAL HEALTH CORP","filed_at":"2026-04-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:31.905028+00:00","generated_at":"2026-05-15T03:42:36.968967+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Brazilian MAPA bans Phibro's virginiamycin and bacitracin growth promoters; 180-day transition","bullets":["MAPA Ordinance 1617 prohibits import, manufacture, marketing and use of antimicrobial feed additives including virginiamycin and bacitracin for growth promotion.","Transition period of 180 days from April 27, 2026; products can still be sold under current labels during that time.","Phibro expects new therapeutic registrations for virginiamycin in cattle and broilers during transition; bacitracin already has therapeutic claims.","Company expects limited impact on fiscal year 2026 results; also launching PhibroVet digital prescription platform.","Additional details to be provided on May 7, 2026 earnings call."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-049485","json":"https://secwatch.observer/filing/0001104659-26-049485.json","markdown":"https://secwatch.observer/filing/0001104659-26-049485.md","text":"https://secwatch.observer/filing/0001104659-26-049485.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1069899/000110465926049485/0001104659-26-049485-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1069899/000110465926049485/tm2612861d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T03:42:36.968967+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}